<DOC>
	<DOCNO>NCT00929058</DOCNO>
	<brief_summary>Rationale : The introduction angiogenesis inhibitor remarkably improve treatment patient several type cancer . One common side effect angiogenesis inhibitor hypertension . In patient treated bevacizumab hypertension overall incidence 32 % . The etiology hypertension cause treatment angiogenesis inhibitor unclear . Objective : To study arterial bevacizumab infusion cause acute vasoconstriction use plethysmography healthy volunteer .</brief_summary>
	<brief_title>Bevacizumab Vasoconstriction</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male 1850 year old normal result glucose , lipids creatinine inform consent History abuse drug alcohol History malignant disease First degree relative history cancer age 50 First degree relative history premature cardiovascular disease Current use medication Clinical evidence cardiac pulmonary disease Hypertension ( systolic &gt; 140mmHg , diastolic &gt; 90mmHg ) Diabetes mellitus smoke history thombosis family history recurrent thrombosis abnormality ECG</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>